* HYPHEN BIOMED *
1999 - IDF
Neuville-sur-Oise
(near Paris)
www.hyphen-biomed.com Design, Diagnostics
(also, Discovery, Diagnostics)
Key words: Research reagents, Thrombosis, Haemostasis, Auto-Immunity, Zymutest
Mission: to develop a full line of innovative kits in diagnostic and research reagents and biochemicals, manual or automated, designed with clotting, chromogenic or immunological methods, for the exploration of Thrombosis, Haemostasis, Fibrinolysis and Auto-Immunity
Clients: Research labs, Pharmaceutical industry
jamiral@hyphen-biomed.com
Age: 13 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Personal venture |
Managing Dir.-CEO: Amiral (Jean) [born 1952, Ph.D., Immunologist, Biochemist, ex-Serbio Stago (CSO)]
Sc.Dir.-CSO: Vissac (Anne Marie) [born 1956, ex-Project Leader Serbio Stago]
Fin.Dir.-CFO:
BusDev (& sales): Penissard (Véronique)
Financers (Hist.): privately owned, IDF Développement, Banque Populaire | Turnover (M€) : 3.7 (2009), 3.0 (2008), 2.0 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Cardiovasc
Position : Trade
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 1999 .01 | Company founded by Jean Amiral and Anne Marie Vissac, in the venture incubator of Conflans-Sainte-Honorine (near Paris) | ORGF | [0 year] | Actualisation / Updating: 6-May-2011 |
|
